Figure 1.
Comparison of various survival endpoints between patients who were treated with dasatinib and nilotinib in matched cohort. (A) Overall survival. (B) Event free survival. (C) Transformation free survival. (D) Failure free survival.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.